Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rachel Dalthorp

Neurology Moore, OK Medical Doctor

NPI 1811218803 CMS profile 556979

1105 Sw 30Th Ct, Moore, OK 73160

Open in the dashboard

General payments

$116,355

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Dalthorp of Moore, OK is reported in the CMS Open Payments database as having received $116,355 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,796 2
2024 General $499 10
2023 General $4,824 9
2022 General $289 3
2021 General $30,376 43
2020 General $20,191 28
2019 General $57,380 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Dalthorp
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Rachel Dalthorp were reported at $2,796. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Rachel Dalthorp Neurology median Middle half National median
2019 $57,380 $474 $118–$2,177 $163
2020 $20,191 $367 $82–$2,309 $114
2021 $30,376 $438 $104–$2,547 $132
2022 $289 $442 $103–$2,388 $149
2023 $4,824 $464 $119–$2,312 $160
2024 $499 $468 $119–$2,323 $164
2025 $2,796 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $99,790 159 payments
  2. Sage Therapeutics, Inc. $9,860 14 payments
  3. Biogen, Inc. $4,681 7 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,404 1 payment
  5. Neuronetics, Inc. $436 9 payments
  6. Allergan Inc. $139 17 payments
  7. E.R. Squibb & Sons, L.L.C. $24 1 payment
  8. Ironshore Pharmaceuticals Inc. $13 1 payment
  9. Organon LLC $7 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $72,685 44 payments
  2. Consulting Fee $32,294 18 payments
  3. Travel and Lodging $7,530 22 payments
  4. Food and Beverage $3,846 126 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $99,672 155 payments
  2. ZULRESSO Psychiatrypsychology $3,664 10 payments
  3. ZULRESSO Psychiatry/Psychology $3,424 3 payments
  4. ZURZUVAE $2,772 1 payment
  5. Neurostar TMS Therapy System $436 9 payments
  6. INVEGA TRINZA $144 3 payments
  7. INVEGA SUSTENNA $121 7 payments
  8. BOTOX $97 11 payments
  9. VRAYLAR $43 6 payments
  10. COBENFY $24 1 payment
  11. Other $21 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record